Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
Enliven Therapeutics reports clinical-stage biopharmaceutical developments for a small-molecule oncology pipeline led by ELVN-001, a kinase inhibitor designed to target the BCR::ABL gene fusion in chronic myeloid leukemia. News commonly covers ENABLE clinical-trial updates, CML data presentations, regulatory-development topics, quarterly financial results, and preparation for later-stage development.
Company updates also include leadership and board changes, Nasdaq inducement grants, investor-conference participation, and descriptions of Enliven's precision oncology discovery process built around clinically validated biological targets and differentiated chemistry.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Enliven Therapeutics announced the successful completion of its merger with Imara, which will enhance its focus on precision oncology through small molecule kinase inhibitors. The new company will trade on Nasdaq under the ticker symbol ELVN starting February 24, 2023. Concurrently, Enliven secured a $165 million private placement, ensuring a cash runway into early 2026. Key clinical candidates include ELVN-001, targeting chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor for non-small cell lung cancer. The merger is positioned to accelerate development and deliver value to shareholders.